Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy
Today, cardiovascular diseases remain the leading cause of morbidity and mortality globally. Hyperlipidemia and dyslipidemia are key points in the occurrence and progression of CVDs, as well as the development of its complications. Elevated low density lipoprotein cholesterol (LDL-C) is the target o...
Main Authors: | I. A. Alekseeva, T. E. Kolmakova, M. B. Ezhov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-10-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/3713 |
Similar Items
-
Features of using of a fixed combination of rosuvastatin and ezetimibe for effective hypolipidemic therapy
by: I. A. Alekseeva, et al.
Published: (2020-10-01) -
Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
by: Kim CH, et al.
Published: (2017-12-01) -
Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial
by: Antonio Carlos Amedeo Vattimo, MD, MSc, et al.
Published: (2020-01-01) -
Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis
by: Yang H, et al.
Published: (2020-01-01) -
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
by: Farnier Michel, et al.
Published: (2011-11-01)